IPM grew 19 percent in March, brands like Calpol, Augmentin observed highest growth: IQVIA
New Delhi: The Indian pharmaceutical market reported double-digit growth of 19 percent in the month of March 2023, according to IQVIA. The Total Sales Audit (TSA) valued at Rs 200,507 crore with growth of 8 percent as of Moving Annual Turnover (MAT) March 2023 and Rs 17,107 crore for March month with growth of 19 percent was recorded. On the other hand, the Stockist Sales Audit (SSA) has...
New Delhi: The Indian pharmaceutical market reported double-digit growth of 19 percent in the month of March 2023, according to IQVIA.
The Total Sales Audit (TSA) valued at Rs 200,507 crore with growth of 8 percent as of Moving Annual Turnover (MAT) March 2023 and Rs 17,107 crore for March month with growth of 19 percent was recorded. On the other hand, the Stockist Sales Audit (SSA) has been valued at Rs 169,705 crore with growth of 7 percent as of MAT March and Rs 14,414 crore for March month with growth of 19%.
As per the report, except Antidiabetic, all therapies exhibited double digit growth rate while Anti-infectives followed by Respiratory posted highest growth at 50 percent and 49 percent respectively. Last month, in February, Respiratory was ahead and registered at 55 percent, however, this month it slipped to second position after anti-infectives.
Performance of Derma and anti-diabetic showed single digit growth at 6 percent and 8 percent valued at Rs 1102 crore and Rs 1528 crore respectively.
Pharma firms including Abbott, Alkem, Intas, Torrent and Aristo have shown improvement in market share for the month of March as compared to February 2023. Meanwhile, Sun Pharma, Cipla, Mankind, Lupin, and Macleods reflected dip in market share for the current month as compared to previous month.
However, Sun Pharma held 7.4 percent of the market share among top ten firms that included Torrent Pharma, Abbott, Cipla, Mankind, Intas, Alkem, Lupin, Macleods and Aristo.
Among top ten firms for the month, Aristo posted highest growth of 36 percent valued at Rs 549 crore, followed by Alkem, Mankind, Macleods on Month level, while on MAT level, Intas has reflected the highest growth at 16 percent followed by Torrent and Alkem.
In the month of March (in comparison to Feb’23), among the top 25 companies Sun Pharma has maintained its top position in the IPM with a market share of 7.4 percent. Aristo improved by 2 ranks to reach 10th position. Emcure, Sanofi and Himalaya improved by 1 rank each to reach 14th, 20th and 25th positions respectively.
As per MAT March (in comparison to Feb’23), among the top 25 companies Sun Pharma has maintained its top position in the IPM with a market share of 8%. All companies maintained their ranks for MAT Mar’23, except Aristo improved 1 rank to reach 11th position.
Augmentin identified itself as the topmost brand with 77 crores of sales. Among top 10 brands for the month, highest growth was observed by Calpol, Monocef and Augmentin with a growth of 106%, 72% & 45% each respectively.
Mixtard, Glycomet-GP, Foracort, Lantus, Clavam, Pan and Thyronorm were registered as the other brands in the top ten list for March.
Star brands of the month
Among the Top 25 products as per Mar’23 Month (in comparison to Feb’23 Month), Augmentin maintained its number one position at month level with a growth of 45%. Glycomet-GP gained 1 rank to secure 3rd position, respectively.
Lantus gained 2 ranks to secure 6th position with a growth of -3%. While, Monocef gained 4 ranks to secure 5th position with a growth of 72%. Calpol, Pan gained 5 ranks to secure 8th, 9th position respectively with a growth of 106%, 17% each respectively.
Liv-52 gained 6 ranks to secure 15th position with a growth of 9%, and T-Bact gained 17 ranks to secure 23rd position with a growth of 27%.
Talking about the trends, Indian companies registered growth of 20% whereas MNC’s registered a growth of 14% for March. Further, Acute showed growth of 22% whereas Chronic showed growth of 15% for the month.
An insight of top therapy trends, exhibited highest growth of 24% by Cilnidipine in cardiac. In Anti-Infective, Azithromycin Oral Solids posted 123% growth which is highest amongst top therapies.
The top contributing subgroup in gastrointestinal (GI) therapy with value of around 127 crore growing at 15% was grabbed by Pantopr. + Domperid. In anti diabetic, Fast Acting subgroup posted highest growth of 16%, while in Vibrating Mesh Nebulizers (VMN) therapy, food supplements was the top contributing subgroup with 168 crore of sales posted growth of 14%.
In Respiratory market, cough prep was observed to be top contributing one with 282 crore of sales and posted growth of 123%. While, in pain market, paracetamol oral solids, liquids and inj contributed ~ 182 crore of sales with 103%, 67% and 47% growth, respectively.
Emollients protectives registered highest sales of 129 crore in derma market with 16% growth while the highest growth of 23% was observed in Mupirocin. In Neuro therapy, levetiracetam was the top valued subgroup with 82 crores of sales and 10% growth.
In Gynaec therapy, conv iron solids, liquids and inj. together have contributed ~274 crore of sales to the entire therapy. Amongst the top Gynae therapies, Dydrogesterone posted highest growth of 40%.
Key changes
Among the top 50 brands of the industry, PTR changes reflected in SKUs of the following brands: Duphaston; Udiliv; Augmentin; Azithral; Azithral; Clavam; Ecosprin-Av; Glycomet-Gp; Glycomet-Gp; Levipil; Levipil; Manforce; Manforce; Manforce; Moxikind-Cv; Pan; Thyronorm; Thyronorm; Thyronorm; Thyronorm; Thyronorm; Vertin; Augmentin; Betadine; Rantac.
2 Corporates and Labs were introduced in March dataset, while 4 brand transfers were registered.
